DK3658557T3 - Tyk2-inhibitorer og anvendelser deraf - Google Patents

Tyk2-inhibitorer og anvendelser deraf Download PDF

Info

Publication number: DK3658557T3
Authority: DK; Denmark
Prior art keywords: tyk2 inhibitors; tyk2; inhibitors
Prior art date: 2017-07-28

Application number

DK18837151.2T

Other languages

English (en)

Inventor

Craig E Masse

Jeremy Robert Greenwood

Sayan Mondal

Scott D Cowen

Thomas H Mclean

Original Assignee

Takeda Pharmaceuticals Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-07-28

Filing date

2018-07-26

Publication date

2024-07-29

2018-07-26 Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co

2024-07-29 Application granted granted Critical

2024-07-29 Publication of DK3658557T3 publication Critical patent/DK3658557T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Obesity (AREA)
Oncology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Emergency Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK18837151.2T 2017-07-28 2018-07-26 Tyk2-inhibitorer og anvendelser deraf DK3658557T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201762538536P	2017-07-28	2017-07-28
US201762560615P	2017-09-19	2017-09-19
US201862664048P	2018-04-27	2018-04-27
PCT/US2018/043917 WO2019023468A1 (en)	2017-07-28	2018-07-26	TYK2 INHIBITORS AND USES THEREOF

Publications (1)

Publication Number	Publication Date
DK3658557T3 true DK3658557T3 (da)	2024-07-29

Family

ID=65040855

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK18837151.2T DK3658557T3 (da)	2017-07-28	2018-07-26	Tyk2-inhibitorer og anvendelser deraf

Country Status (23)

Country	Link
US (9)	US11046698B2 (da)
EP (2)	EP3658557B1 (da)
JP (3)	JP7216705B2 (da)
KR (2)	KR102717819B1 (da)
CN (4)	CN121991078A (da)
AU (3)	AU2018306444B2 (da)
CA (1)	CA3070621A1 (da)
DK (1)	DK3658557T3 (da)
ES (1)	ES2994013T3 (da)
FI (1)	FI3658557T3 (da)
HR (1)	HRP20241016T1 (da)
HU (1)	HUE068033T2 (da)
IL (2)	IL317854A (da)
LT (1)	LT3658557T (da)
MX (2)	MX2020001103A (da)
MY (1)	MY205416A (da)
PL (1)	PL3658557T3 (da)
PT (1)	PT3658557T (da)
RS (1)	RS65838B1 (da)
SG (1)	SG11202000714QA (da)
SI (1)	SI3658557T1 (da)
TW (3)	TWI899935B (da)
WO (1)	WO2019023468A1 (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2930585T3 (es)	2015-02-27	2022-12-19	Nimbus Lakshmi Inc	Inhibidores de TYK2 y usos de los mismos
JP6802263B2 (ja)	2015-09-02	2020-12-16	ニンバスラクシュミ，インコーポレイテッド	Ｔｙｋ２阻害剤およびその使用
WO2018010789A1 (en)	2016-07-13	2018-01-18	Humabs Biomed Sa	Novel antibodies specifically binding to zika virus epitopes and uses thereof
JP7082120B2 (ja)	2016-10-21	2022-06-07	ニンバスラクシュミ，インコーポレイテッド	Ｔｙｋ２阻害剤およびその使用
US10508113B2 (en)	2018-03-12	2019-12-17	Abbvie Inc.	Inhibitors of tyrosine kinase 2 mediated signaling
ES2938751T3 (es) *	2018-09-10	2023-04-14	Lilly Co Eli	Derivados de pirazol[1,5-a]pirimidina-3-carboxamida útiles en el tratamiento de la psoriasis y el lupus eritematoso sistémico
CA3115088A1 (en) *	2018-10-15	2020-04-23	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
IL282254B2 (en)	2018-10-30	2025-08-01	Kronos Bio Inc	Compounds, compositions, and methods for modulating cdk9 activity
AR117177A1 (es)	2018-12-10	2021-07-14	Lilly Co Eli	DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa
MX2021009555A (es) *	2019-02-07	2021-10-13	Ventyx Biosciences Inc	Ligandos de pseudocinasa tyk2.
IL286248B2 (en)	2019-03-11	2025-12-01	Alumis Inc	Tyk2 inhibitors and uses thereof
EA202192625A1 (ru) *	2019-03-26	2022-03-21	Вентикс Байосайенсес, Инк.	Лиганды псевдокиназы tyk2
KR102938141B1 (ko) *	2019-11-08	2026-03-11	벤틱스 바이오사이언스, 인크.	Tyk2 슈도키나제 리간드
AR121251A1 (es) *	2020-02-12	2022-05-04	Lilly Co Eli	Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida
US12516063B2 (en)	2020-02-12	2026-01-06	Eli Lilly And Company	Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives for treating autoimmune diseases
US11116737B1 (en)	2020-04-10	2021-09-14	University Of Georgia Research Foundation, Inc.	Methods of using probenecid for treatment of coronavirus infections
CN114437077B (zh) *	2020-11-04	2024-01-30	浙江同源康医药股份有限公司	用作激酶抑制剂的化合物及其应用
CN117043164A (zh) *	2021-01-19	2023-11-10	安锐生物医药科技(广州)有限公司	咪唑并哒嗪或吡唑并嘧啶化合物和组合物
CN117083268B (zh)	2021-03-16	2024-07-30	安锐生物医药科技(广州)有限公司	氨基杂芳基化合物和组合物
CN115322105A (zh) *	2021-05-11	2022-11-11	江苏润安制药有限公司	一种合成艾拉莫德关键中间体的方法
EP4408527A2 (en)	2021-09-30	2024-08-07	Bristol-Myers Squibb Company	Methods for determining responsiveness to tyk2 inhibitors
EP4423086A1 (en)	2021-10-25	2024-09-04	Kymera Therapeutics, Inc.	Tyk2 degraders and uses thereof
CN118974052A (zh) *	2022-03-25	2024-11-15	武田药品工业株式会社	Tyk2抑制剂的固体形式和使用方法
WO2023183908A1 (en) *	2022-03-25	2023-09-28	Nimbus Lakshmi, Inc.	Tyk2 inhibitor synthesis and intermediates thereof
AR128868A1 (es) *	2022-03-25	2024-06-19	Nimbus Lakshmi Inc	Formulaciones de inhibidor de tyk2 y métodos para elaborarlas
US20250213572A1 (en) *	2022-03-25	2025-07-03	Takeda Pharmaceutical Company Limited	Tyk2 inhibitors and uses thereof
CN115057820A (zh) *	2022-08-04	2022-09-16	东莞理工学院	一种以乙酰丙酸合成4,5-二氢-6-甲基哒嗪-3(2h)-酮的方法
WO2024262911A1 (ko) *	2023-06-19	2024-12-26	주식회사 에이조스바이오	신규 피라졸로 피리미딘계 화합물 및 이의 용도
AU2024344754A1 (en)	2023-09-21	2026-04-02	Takeda Pharmaceutical Company Limited	Tyk2 inhibitors for use in the treatment of inflammatory bowel disease
WO2025061180A1 (zh) *	2023-09-22	2025-03-27	杭州多域生物技术有限公司	含氮并环类化合物、其药物组合物及其应用
WO2025107861A1 (zh) *	2023-11-24	2025-05-30	苏州科睿思制药有限公司	Zasocitinib的晶型及其制备方法和用途
WO2025168035A1 (zh) *	2024-02-07	2025-08-14	合肥羿科医药有限公司	杂环类化合物、其药物组合物及其应用
WO2025191534A1 (en)	2024-03-14	2025-09-18	Assia Chemical Industries Ltd.	Solid state forms of zasocitinib and process for preparation thereof
WO2025214467A1 (zh) *	2024-04-12	2025-10-16	江苏恒瑞医药股份有限公司	氨基取代的杂芳环类化合物、其制备方法及其在医药上的应用
WO2026033474A1 (en)	2024-08-08	2026-02-12	Takeda Pharmaceutical Company Limited	Deuterated compounds and uses thereof
CN121909196A (zh) *	2024-08-15	2026-04-21	成都肯迪特生物医药科技有限公司	一种具有tyk2抑制作用的化合物及其制备方法和用途

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5516931A (en)	1982-02-01	1996-05-14	Northeastern University	Release tag compounds producing ketone signal groups
US4709016A (en)	1982-02-01	1987-11-24	Northeastern University	Molecular analytical release tags and their use in chemical analysis
US5650270A (en)	1982-02-01	1997-07-22	Northeastern University	Molecular analytical release tags and their use in chemical analysis
US4650750A (en)	1982-02-01	1987-03-17	Giese Roger W	Method of chemical analysis employing molecular release tag compounds
DE4310970A1 (de)	1993-04-03	1994-10-06	Huels Chemische Werke Ag	Farblose und transparente, amorph zu verarbeitende Polyamidformmassen mit guter Spannungsrißbeständigkeit und Schlagzähigkeit
EA006227B1 (ru)	1999-12-10	2005-10-27	Пфайзер Продактс Инк.	СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
PE20020354A1 (es)	2000-09-01	2002-06-12	Novartis Ag	Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7071189B2 (en)	2001-04-27	2006-07-04	Zenyaku Kogyo Kabushiki Kaisha	Heterocyclic compound and antitumor agent containing the same as active ingredient
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
WO2004019973A1 (en)	2002-08-14	2004-03-11	Atugen Ag	Use of protein kinase n beta
US7161003B1 (en)	2002-09-04	2007-01-09	Schering Corporation	Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en)	2002-09-04	2007-03-27	Schering Corpoartion	Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
MXPA05002571A (es)	2002-09-04	2005-09-08	Schering Corp	Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
US8580782B2 (en)	2002-09-04	2013-11-12	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en)	2002-09-04	2006-10-10	Schering Corporation	Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) *	2002-09-04	2007-04-17	Schering Corporation	Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7084271B2 (en)	2002-09-04	2006-08-01	Schering Corporation	Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en)	2002-09-04	2014-03-18	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
KR20050115252A (ko) *	2003-02-28	2005-12-07	데이진 화-마 가부시키가이샤	피라졸로[1,5-ａ]피리미딘 유도체
GB0304665D0 (en) *	2003-02-28	2003-04-02	Teijin Ltd	Compounds
US20070179161A1 (en)	2003-03-31	2007-08-02	Vernalis (Cambridge) Limited.	Pyrazolopyrimidine compounds and their use in medicine
JP2006523237A (ja)	2003-04-03	2006-10-12	セマフォアファーマシューティカルズ，インコーポレイテッド	Ｐｉ−３キナーゼインヒビタープロドラッグ
US7425553B2 (en)	2003-05-30	2008-09-16	Gemin X Pharmaceuticals Canada Inc.	Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
CA2531069A1 (en)	2003-07-03	2005-01-27	The Trustees Of The University Of Pennsylvania	Inhibition of syk kinase expression
MXPA06002618A (es)	2003-09-09	2006-06-05	Ono Pharmaceutical Co	Antagonistas del factor de liberacion de corticotropina (crf) y compuestos heterobiciclicos.
DE102004008807A1 (de) *	2004-02-20	2005-09-08	Bayer Cropscience Ag	Pyrazolopyrimidine
EP1761540B1 (en)	2004-05-13	2016-09-28	Icos Corporation	Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
JP2006160628A (ja)	2004-12-03	2006-06-22	Ishihara Sangyo Kaisha Ltd	アデノシンＡ２ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
JP4801096B2 (ja)	2005-01-19	2011-10-26	ライジェルファーマシューティカルズ，インコーポレイテッド	２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
DE102005007534A1 (de) *	2005-02-17	2006-08-31	Bayer Cropscience Ag	Pyrazolopyrimidine
EP2757099B1 (en)	2005-05-12	2017-08-23	AbbVie Bahamas Limited	Apoptosis promoters
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
US7402325B2 (en)	2005-07-28	2008-07-22	Phoenix Biotechnology, Inc.	Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US20070078136A1 (en) *	2005-09-22	2007-04-05	Bristol-Myers Squibb Company	Fused heterocyclic compounds useful as kinase modulators
CA2624882C (en) *	2005-10-06	2014-05-20	Schering Corporation	Pyrazolopyrimidines as protein kinase inhibitors
BRPI0616985B1 (pt)	2005-10-06	2021-10-26	Merck Sharp & Dohme Corp.	Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
AU2006302179C1 (en)	2005-10-07	2013-06-20	Exelixis, Inc.	N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
US7528143B2 (en)	2005-11-01	2009-05-05	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
CN103214484B (zh)	2005-12-13	2016-07-06	因塞特控股公司	作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
DOP2006000268A (es)	2005-12-22	2007-07-31	Pfizer Prod Inc	Agentes antibacterianos
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
RU2439074C2 (ru)	2006-04-26	2012-01-10	Ф. Хоффманн-Ля Рош Аг	ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К)
PL2526933T3 (pl)	2006-09-22	2015-08-31	Pharmacyclics Llc	Inhibitory kinazy tyrozynowej Brutona
CA2670083A1 (en)	2006-11-20	2008-05-29	Alantos Pharmaceuticals Holding, Inc.	Heterobicyclic metalloprotease inhibitors
AU2008223348A1 (en)	2007-03-07	2008-09-12	Alantos Pharmaceuticals Holding, Inc.	Metalloprotease inhibitors containing a heterocyclic moiety
US8486941B2 (en)	2007-03-12	2013-07-16	Ym Biosciences Australia Pty Ltd	Phenyl amino pyrimidine compounds and uses thereof
US8394794B2 (en)	2007-03-23	2013-03-12	Regents Of The University Of Minnesota	Therapeutic compounds
PE20090717A1 (es)	2007-05-18	2009-07-18	Smithkline Beecham Corp	Derivados de quinolina como inhibidores de la pi3 quinasa
TWI444382B (zh)	2008-03-11	2014-07-11	Incyte Corp	作為ｊａｋ抑制劑之氮雜環丁烷及環丁烷衍生物
UY31750A (es)	2008-04-07	2009-12-14	Irm Llc	Compuestos y composiciones como inhibidores de quinasa
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
CN102271515B (zh)	2008-10-31	2014-07-02	健泰科生物技术公司	吡唑并嘧啶jak抑制剂化合物和方法
WO2010086040A1 (en)	2009-01-29	2010-08-05	Biomarin Iga, Ltd.	Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) *	2009-07-09	2011-08-31	Array Biopharma Inc	Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
KR20120104521A (ko)	2009-09-11	2012-09-21	사일린 파마슈티칼스, 인크	약제학적으로 유용한 헤테로사이클－치환된 락탐
RU2607453C2 (ru)	2009-12-04	2017-01-10	Сенхва Байосайенсиз, Инк.	Пиразолопиримидины и родственные гетероциклы как ск2 ингибиторы
US20110207736A1 (en)	2009-12-23	2011-08-25	Gatekeeper Pharmaceuticals, Inc.	Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
JP5749341B2 (ja)	2010-08-20	2015-07-15	ハチソンメディファーマリミテッド	ピロロピリミジン化合物およびその使用
CA2820362C (en) *	2010-12-08	2020-03-24	The United States Of America, As Represented By The Secretary, Departmt Of Health And Human Services	Substituted pyrazolopyrimidines as glucocerebrosidase activators
WO2012170827A2 (en)	2011-06-08	2012-12-13	Cylene Pharmaceuticals, Inc.	Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
WO2013052263A2 (en)	2011-09-16	2013-04-11	Microbiotix, Inc.	Antifungal compounds
IN2014DN07384A (da)	2012-03-09	2015-04-24	Lexicon Pharmaceuticals Inc
AR093403A1 (es)	2012-11-08	2015-06-03	Bristol Myers Squibb Co	COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA UTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL23 Y/O INFa
JP6377068B2 (ja)	2012-11-16	2018-08-22	ユニバーシティ・ヘルス・ネットワーク	ピラゾロピリミジン化合物
SMT202000713T1 (it)	2012-12-07	2021-03-15	Vertex Pharma	Pirazolo [1,5-a] pirimidine utili come inibitori dell'atr chinasi per il trattamento di malattie del cancro
EP2970288A1 (en)	2013-03-15	2016-01-20	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EP3080131B1 (en)	2013-12-10	2018-10-10	Bristol-Myers Squibb Company	Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
GB201403093D0 (en)	2014-02-21	2014-04-09	Cancer Rec Tech Ltd	Therapeutic compounds and their use
EP4019518A1 (en)	2014-02-28	2022-06-29	Nimbus Lakshmi, Inc.	Tyk2 inhibitors and uses thereof
EP3805218A1 (en)	2014-04-05	2021-04-14	Syros Pharmaceuticals, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
TW201625563A (zh) *	2014-07-28	2016-07-16	陶氏農業科學公司	具有某些殺蟲效用之分子及與其相關之中間物、組成物及方法（一）
ES2930585T3 (es)	2015-02-27	2022-12-19	Nimbus Lakshmi Inc	Inhibidores de TYK2 y usos de los mismos
CN107530329B (zh)	2015-03-09	2021-10-08	奥瑞基尼探索技术有限公司	用作CDK抑制剂的吡唑并[1，5-a][1，3，5]三嗪和吡唑并[1，5-a]嘧啶衍生物
WO2016144846A1 (en) *	2015-03-12	2016-09-15	Merck Sharp & Dohme Corp.	Pyrazolopyrimidine inhibitors of irak4 activity
WO2017002120A1 (en)	2015-07-02	2017-01-05	Yeda Research And Development Co. Ltd.	Selective inhibitors of senescent cells and uses thereof
CN108024971A (zh)	2015-07-15	2018-05-11	奥列基因发现技术有限公司	作为irak-4抑制剂的取代的氮杂化合物
JP6802263B2 (ja)	2015-09-02	2020-12-16	ニンバスラクシュミ，インコーポレイテッド	Ｔｙｋ２阻害剤およびその使用
US20170116285A1 (en)	2015-10-27	2017-04-27	Microsoft Technology Licensing, Llc	Semantic Location Layer For User-Related Activity
KR102782807B1 (ko)	2015-11-18	2025-03-14	브리스톨-마이어스 스큅 컴퍼니	Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
CN115448916B (zh)	2016-10-14	2026-04-28	武田药品工业株式会社	Tyk2抑制剂及其用途
JP7082120B2 (ja)	2016-10-21	2022-06-07	ニンバスラクシュミ，インコーポレイテッド	Ｔｙｋ２阻害剤およびその使用
TWI868528B (zh)	2017-03-08	2025-01-01	日商武田藥品工業股份有限公司	Ｔｙｋ２抑制劑之生產方法

2018
- 2018-07-26 WO PCT/US2018/043917 patent/WO2019023468A1/en not_active Ceased
- 2018-07-26 KR KR1020207005884A patent/KR102717819B1/ko active Active
- 2018-07-26 RS RS20240886A patent/RS65838B1/sr unknown
- 2018-07-26 EP EP18837151.2A patent/EP3658557B1/en active Active
- 2018-07-26 SI SI201831131T patent/SI3658557T1/sl unknown
- 2018-07-26 ES ES18837151T patent/ES2994013T3/es active Active
- 2018-07-26 JP JP2020504110A patent/JP7216705B2/ja active Active
- 2018-07-26 PL PL18837151.2T patent/PL3658557T3/pl unknown
- 2018-07-26 CN CN202511995600.0A patent/CN121991078A/zh active Pending
- 2018-07-26 HU HUE18837151A patent/HUE068033T2/hu unknown
- 2018-07-26 DK DK18837151.2T patent/DK3658557T3/da active
- 2018-07-26 CA CA3070621A patent/CA3070621A1/en active Pending
- 2018-07-26 MX MX2020001103A patent/MX2020001103A/es unknown
- 2018-07-26 CN CN201880057821.5A patent/CN111194317A/zh active Pending
- 2018-07-26 AU AU2018306444A patent/AU2018306444B2/en active Active
- 2018-07-26 PT PT188371512T patent/PT3658557T/pt unknown
- 2018-07-26 LT LTEPPCT/US2018/043917T patent/LT3658557T/lt unknown
- 2018-07-26 IL IL317854A patent/IL317854A/en unknown
- 2018-07-26 US US16/046,481 patent/US11046698B2/en active Active
- 2018-07-26 KR KR1020247033787A patent/KR20240153614A/ko active Pending
- 2018-07-26 MY MYPI2020000459A patent/MY205416A/en unknown
- 2018-07-26 CN CN202311776307.6A patent/CN117946115A/zh active Pending
- 2018-07-26 CN CN202311772622.1A patent/CN117946114A/zh active Pending
- 2018-07-26 FI FIEP18837151.2T patent/FI3658557T3/fi active
- 2018-07-26 SG SG11202000714QA patent/SG11202000714QA/en unknown
- 2018-07-26 EP EP24179388.4A patent/EP4438117A3/en active Pending
- 2018-07-26 IL IL271999A patent/IL271999B2/en unknown
- 2018-07-26 HR HRP20241016TT patent/HRP20241016T1/hr unknown
- 2018-07-27 TW TW113112846A patent/TWI899935B/zh active
- 2018-07-27 TW TW114133811A patent/TW202547839A/zh unknown
- 2018-07-27 TW TW107126251A patent/TWI840332B/zh active
2019
- 2019-04-12 US US16/382,869 patent/US10562907B2/en active Active
- 2019-04-12 US US16/382,734 patent/US10508120B2/en active Active
- 2019-04-12 US US16/382,907 patent/US10570145B2/en active Active
- 2019-04-12 US US16/382,824 patent/US10562906B2/en active Active
- 2019-04-12 US US16/382,680 patent/US10577373B2/en active Active
2020
- 2020-01-28 MX MX2023004593A patent/MX2023004593A/es unknown
2021
- 2021-03-23 US US17/210,066 patent/US20220356184A1/en not_active Abandoned
- 2021-09-14 US US17/447,648 patent/US20230056447A1/en not_active Abandoned
2022
- 2022-11-28 AU AU2022279375A patent/AU2022279375A1/en not_active Abandoned
2023
- 2023-01-20 JP JP2023007066A patent/JP2023052540A/ja active Pending
2024
- 2024-07-09 AU AU2024204726A patent/AU2024204726A1/en active Pending
2025
- 2025-01-18 US US19/031,891 patent/US20250326760A1/en active Pending
- 2025-02-28 JP JP2025031273A patent/JP2025098031A/ja active Pending

Also Published As

Publication number	Publication date
US20190241575A1 (en)	2019-08-08
TW202502769A (zh)	2025-01-16
US20190241577A1 (en)	2019-08-08
SG11202000714QA (en)	2020-02-27
US10577373B2 (en)	2020-03-03
PT3658557T (pt)	2024-09-11
TWI840332B (zh)	2024-05-01
EP3658557A4 (en)	2020-12-09
MX2023004593A (es)	2023-05-08
EP3658557A1 (en)	2020-06-03
US10562907B2 (en)	2020-02-18
IL271999B1 (en)	2025-02-01
TWI899935B (zh)	2025-10-01
US10570145B2 (en)	2020-02-25
MY205416A (en)	2024-10-21
HRP20241016T1 (hr)	2024-11-08
LT3658557T (lt)	2024-09-25
IL317854A (en)	2025-02-01
SI3658557T1 (sl)	2024-10-30
IL271999A (en)	2020-02-27
IL271999B2 (en)	2025-06-01
TW201920178A (zh)	2019-06-01
WO2019023468A1 (en)	2019-01-31
RS65838B1 (sr)	2024-09-30
US20190256519A1 (en)	2019-08-22
US11046698B2 (en)	2021-06-29
CN121991078A (zh)	2026-05-08
AU2018306444B2 (en)	2022-11-17
BR112020001714A2 (pt)	2020-07-21
EP4438117A2 (en)	2024-10-02
US10562906B2 (en)	2020-02-18
US20190248797A1 (en)	2019-08-15
US20190241576A1 (en)	2019-08-08
CA3070621A1 (en)	2019-01-31
CN111194317A (zh)	2020-05-22
AU2018306444A1 (en)	2020-02-06
MX2020001103A (es)	2020-08-17
RU2020102476A (ru)	2021-08-30
FI3658557T3 (fi)	2024-07-30
JP2020528909A (ja)	2020-10-01
HUE068033T2 (hu)	2024-12-28
ES2994013T3 (en)	2025-01-15
US20250326760A1 (en)	2025-10-23
US20220356184A1 (en)	2022-11-10
JP7216705B2 (ja)	2023-02-02
EP4438117A3 (en)	2024-12-18
TW202547839A (zh)	2025-12-16
PL3658557T3 (pl)	2024-10-14
KR20200035293A (ko)	2020-04-02
US20230056447A1 (en)	2023-02-23
RU2020102476A3 (da)	2021-12-10
JP2023052540A (ja)	2023-04-11
US10508120B2 (en)	2019-12-17
KR102717819B1 (ko)	2024-10-14
CN117946114A (zh)	2024-04-30
EP3658557B1 (en)	2024-06-05
US20190031664A1 (en)	2019-01-31
AU2024204726A1 (en)	2024-07-25
KR20240153614A (ko)	2024-10-23
JP2025098031A (ja)	2025-07-01
AU2022279375A1 (en)	2023-01-19
CN117946115A (zh)	2024-04-30

Publication	Publication Date	Title
DK3870579T3 (da)	2025-01-02	Tyk2-inhibitorer og anvendelser deraf
IL282090A (en)	2021-05-31	Tyk2 inhibitors and uses thereof
IL271999A (en)	2020-02-27	TYK2 inhibitors and uses thereof
DK3727426T3 (da)	2026-02-02	Incretinanaloger og anvendelser deraf
EP3526222A4 (en)	2020-08-26	TYK2 INHIBITORS AND THEIR USES
IL266109A (en)	2019-06-30	tyk2 inhibitors and uses thereof
DK3610005T3 (da)	2021-12-13	Peptidligase og anvendelse deraf
IL283409A (en)	2021-07-29	tyk2 inhibitors and uses thereof
DK3389658T3 (da)	2021-01-11	Glycosidasehæmmere og anvendelser deraf
DK3452463T3 (da)	2021-04-26	Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
IL284799A (en)	2021-08-31	Tyk2 inhibitors and uses thereof
DK3621694T5 (da)	2024-09-02	Lrrc33-inhibitorer og anvendelse heraf
DK3474883T3 (da)	2022-08-29	Komplementinhibitorer og anvendelser deraf
DK3543240T3 (da)	2022-10-10	URAT1-inhibitor og anvendelse deraf
DK3532459T3 (da)	2023-10-30	Lsd1-hæmmere og medicinske anvendelser deraf
DK3426243T3 (da)	2021-07-19	3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
DK3321279T3 (da)	2020-03-09	Exenatidmodificeringsmiddel og anvendelse deraf
DK3280405T3 (da)	2021-09-06	Inhibitorer og anvendelser deraf
DK3365321T3 (da)	2024-01-15	Solabegron-zwitterion og anvendelser deraf
DK3615502T3 (da)	2023-09-25	Terapeutiske forbindelser og fremgangsmåder
DK3796979T3 (da)	2025-07-14	Mir-181-hæmmere og anvendelser deraf
DK3724196T3 (da)	2023-01-16	Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere
DK3573611T3 (da)	2022-04-11	Amidforbindelser og anvendelse deraf
DK3180335T3 (da)	2021-08-09	Cytokrom-p450-inhibitorer og anvendelser deraf
DK3337567T3 (da)	2021-12-06	Hiv-1-proteasehæmmere og anvendelser deraf